<- Go Home
Galecto, Inc.
Galecto, Inc., a clinical-stage biotechnology company, develops molecule therapeutics for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company develops GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 and GB1211, an oral small molecule inhibitor of galectin-3 to treat multiple types of oncology and liver disease indications. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.
Market Cap
$35.6M
Volume
333.2K
Cash and Equivalents
$7.6M
EBITDA
-$11.9M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$33.60
52 Week Low
$2.01
Dividend
N/A
Price / Book Value
5.34
Price / Earnings
-2.24
Price / Tangible Book Value
5.34
Enterprise Value
$29.4M
Enterprise Value / EBITDA
-2.49
Operating Income
-$11.9M
Return on Equity
109.49%
Return on Assets
-43.54
Cash and Short Term Investments
$7.6M
Debt
$72.0K
Equity
$8.0M
Revenue
N/A
Unlevered FCF
-$7.0M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium